JPWO2020225375A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020225375A5 JPWO2020225375A5 JP2021566160A JP2021566160A JPWO2020225375A5 JP WO2020225375 A5 JPWO2020225375 A5 JP WO2020225375A5 JP 2021566160 A JP2021566160 A JP 2021566160A JP 2021566160 A JP2021566160 A JP 2021566160A JP WO2020225375 A5 JPWO2020225375 A5 JP WO2020225375A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- cancer
- prior
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000002626 targeted therapy Methods 0.000 claims 3
- NLPVWMCIPLKCGB-UHFFFAOYSA-N 1H-benzo[7]annulene-2-carboxylic acid Chemical compound C1C(=CC=C2C1=CC=CC=C2)C(=O)O NLPVWMCIPLKCGB-UHFFFAOYSA-N 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 2
- 238000009261 endocrine therapy Methods 0.000 claims 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 1
- 206010061819 Disease recurrence Diseases 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229940125944 selective estrogen receptor degrader Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305593 | 2019-05-09 | ||
| EP19305593.6 | 2019-05-09 | ||
| EP19305679.3 | 2019-05-28 | ||
| EP19305679 | 2019-05-28 | ||
| US201962945311P | 2019-12-09 | 2019-12-09 | |
| US62/945,311 | 2019-12-09 | ||
| PCT/EP2020/062743 WO2020225375A1 (en) | 2019-05-09 | 2020-05-07 | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531898A JP2022531898A (ja) | 2022-07-12 |
| JPWO2020225375A5 true JPWO2020225375A5 (https=) | 2023-05-01 |
| JP2022531898A5 JP2022531898A5 (https=) | 2023-05-01 |
Family
ID=70681807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566160A Ceased JP2022531898A (ja) | 2019-05-09 | 2020-05-07 | 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200352905A1 (https=) |
| EP (1) | EP3965758A1 (https=) |
| JP (1) | JP2022531898A (https=) |
| KR (1) | KR20220006553A (https=) |
| CN (1) | CN114173776A (https=) |
| AU (1) | AU2020268762A1 (https=) |
| BR (1) | BR112021022216A2 (https=) |
| CA (1) | CA3146346A1 (https=) |
| IL (1) | IL287805A (https=) |
| MX (1) | MX2021013711A (https=) |
| SG (1) | SG11202111979SA (https=) |
| TW (1) | TW202110434A (https=) |
| WO (1) | WO2020225375A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7413363B2 (ja) | 2018-09-07 | 2024-01-15 | サノフイ | メチル６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボキシレートの調製方法 |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| KR20220113695A (ko) | 2019-12-09 | 2022-08-16 | 사노피 | 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태 |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| WO2022084280A1 (en) | 2020-10-19 | 2022-04-28 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| EP4247363A1 (en) * | 2020-11-23 | 2023-09-27 | Sanofi | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| TWI837605B (zh) * | 2021-03-09 | 2024-04-01 | 美商美國禮來大藥廠 | 使用serd組合給藥方案治療癌症之方法 |
| CN117042771A (zh) * | 2021-03-09 | 2023-11-10 | 伊莱利利公司 | 使用serd给药方案的组合治疗癌症的方法 |
| TW202400136A (zh) * | 2022-03-13 | 2024-01-01 | 法商賽諾菲公司 | 以安森司群(amcenestrant)治療乳癌 |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19833786A1 (de) * | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| WO2015082990A1 (en) * | 2013-12-06 | 2015-06-11 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
| JP7019422B2 (ja) * | 2015-04-29 | 2022-02-15 | ラジウス ファーマシューティカルズ，インコーポレイテッド | 癌を治療するための方法 |
| SMT202300018T1 (it) * | 2015-12-09 | 2023-03-17 | Univ Illinois | Downregolatori del recettore degli estrogeni a base di benzotiofene |
| LT3416962T (lt) * | 2016-02-15 | 2021-07-12 | Sanofi | 6,7-dihidro-5h-benzo[7]anuleno dariniai kaip estrogenų recepptoriaus moduliatoriai |
| EP3434272A1 (en) * | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
-
2020
- 2020-05-07 BR BR112021022216A patent/BR112021022216A2/pt not_active IP Right Cessation
- 2020-05-07 MX MX2021013711A patent/MX2021013711A/es unknown
- 2020-05-07 EP EP20725471.5A patent/EP3965758A1/en not_active Withdrawn
- 2020-05-07 AU AU2020268762A patent/AU2020268762A1/en not_active Abandoned
- 2020-05-07 KR KR1020217038971A patent/KR20220006553A/ko not_active Ceased
- 2020-05-07 SG SG11202111979SA patent/SG11202111979SA/en unknown
- 2020-05-07 WO PCT/EP2020/062743 patent/WO2020225375A1/en not_active Ceased
- 2020-05-07 CN CN202080048052.XA patent/CN114173776A/zh active Pending
- 2020-05-07 CA CA3146346A patent/CA3146346A1/en active Pending
- 2020-05-07 JP JP2021566160A patent/JP2022531898A/ja not_active Ceased
- 2020-05-08 TW TW109115366A patent/TW202110434A/zh unknown
- 2020-05-08 US US16/870,031 patent/US20200352905A1/en not_active Abandoned
-
2021
- 2021-11-02 IL IL287805A patent/IL287805A/en unknown
-
2023
- 2023-09-01 US US18/241,419 patent/US20240091194A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12280050B2 (en) | Therapeutic compositions, combinations, and methods of use | |
| US20230103007A1 (en) | Combination therapy for treating abnormal cell growth | |
| US20230321097A1 (en) | Methods and compositions for treating abnormal cell growth | |
| JP2022180461A5 (https=) | ||
| JP2022172480A5 (https=) | ||
| US20230201198A1 (en) | Methods of treating abnormal cell growth | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| JPWO2020225375A5 (https=) | ||
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| IL292725A (en) | Benzazepines are combined for the treatment of Tourette syndrome | |
| JP2005503391A5 (https=) | ||
| CN107820424A (zh) | Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型 | |
| EP1485090B1 (en) | Combinations comprising an epothilone derivative and an imidazotetrazinone | |
| CN1537006A (zh) | 含有米尔塔扎平和对乙酰氨基酚或一种非甾类消炎药的用于治疗头痛的联合用药物 | |
| JPWO2021089419A5 (https=) | ||
| JPWO2023194530A5 (https=) | ||
| JPWO2023194528A5 (https=) | ||
| HK1072723B (en) | Combinations comprising an epothilone derivatives and an imidazotetrazinone |